251. Treatment strategies in mastocytosis.
- Author
-
Siebenhaar F, Akin C, Bindslev-Jensen C, Maurer M, and Broesby-Olsen S
- Subjects
- 1-Alkyl-2-acetylglycerophosphocholine Esterase genetics, 1-Alkyl-2-acetylglycerophosphocholine Esterase immunology, Antibodies, Monoclonal, Humanized therapeutic use, Bone and Bones drug effects, Bone and Bones immunology, Bone and Bones pathology, Central Nervous System drug effects, Central Nervous System immunology, Central Nervous System pathology, Dasatinib, Gastrointestinal Tract drug effects, Gastrointestinal Tract immunology, Gastrointestinal Tract pathology, Gene Expression, Humans, Mast Cells immunology, Mast Cells pathology, Mastocytosis genetics, Mastocytosis immunology, Mastocytosis pathology, Omalizumab, Proto-Oncogene Proteins c-kit antagonists & inhibitors, Proto-Oncogene Proteins c-kit genetics, Proto-Oncogene Proteins c-kit immunology, Pyrimidines therapeutic use, Skin drug effects, Skin immunology, Skin pathology, Thiazoles therapeutic use, Antibodies, Anti-Idiotypic therapeutic use, Histamine Antagonists therapeutic use, Mast Cells drug effects, Mastocytosis drug therapy, Protein Kinase Inhibitors therapeutic use
- Abstract
Treatment recommendations for mastocytosis are based mostly on expert opinion rather than evidence obtained from controlled clinical trials. In this article, treatment options for mastocytosis are presented, with a focus on the control of mediator-related symptoms in patients with indolent disease., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF